当前位置:首页 - 行情中心 - 海翔药业(002099) - 财务分析 - 现金流量表

海翔药业

(002099)

  

流通市值:93.87亿  总市值:94.05亿
流通股本:16.16亿   总股本:16.19亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金699,368,481.78344,510,881.751,343,861,950.081,058,386,373.89
  收到的税费返还56,936,665.7532,821,522.6797,432,207.0274,642,507.1
  收到其他与经营活动有关的现金107,995,448.1638,505,632.68105,889,84785,539,886.72
  经营活动现金流入小计864,300,595.69415,838,037.11,547,184,004.11,218,568,767.71
  购买商品、接受劳务支付的现金542,898,159.92266,034,434.68743,428,837.13647,362,510.5
  支付给职工以及为职工支付的现金174,682,411.4594,770,898.09333,163,703.94248,285,496
  支付的各项税费62,035,708.1533,110,944.2760,469,711.3353,127,328.68
  支付其他与经营活动有关的现金83,422,200.3746,791,682.95235,286,881.13130,297,374.59
  经营活动现金流出小计863,038,479.89440,707,959.991,372,349,133.531,079,072,709.77
  经营活动产生的现金流量净额1,262,115.8-24,869,922.89174,834,870.57139,496,057.94
二、投资活动产生的现金流量:
  收回投资收到的现金130,489.88-24,000,000-
  取得投资收益收到的现金7,272,551.356,990,103.35--
  处置固定资产、无形资产和其他长期资产收回的现金净额30,975.8-8,087,222.86126,200
  处置子公司及其他营业单位收到的现金净额---24,000,000
  收到的其他与投资活动有关的现金404,296,712.03388,216,053.0310,038,151.33103,315,802.71
  投资活动现金流入小计411,730,729.06395,206,156.3842,125,374.19127,442,002.71
  购建固定资产、无形资产和其他长期资产支付的现金45,269,659.3834,545,637.96122,109,749.7985,164,590.92
  支付其他与投资活动有关的现金309,402,602.6612,360,237.43447,409,030.4147,580,186.18
  投资活动现金流出小计354,672,262.0446,905,875.39569,518,780.19232,744,777.1
  投资活动产生的现金流量净额57,058,467.02348,300,280.99-527,393,406-105,302,774.39
三、筹资活动产生的现金流量:
  吸收投资收到的现金--1,000,000-
  其中:子公司吸收少数股东投资收到的现金--1,000,000-
  取得借款收到的现金1,304,700,000769,700,0002,506,700,0001,994,700,000
  收到其他与筹资活动有关的现金156,800,00049,400,000266,499,490184,499,490
  筹资活动现金流入小计1,461,500,000819,100,0002,774,199,4902,179,199,490
  偿还债务支付的现金971,500,000479,663,0002,323,697,4501,928,597,450
  分配股利、利润或偿付利息支付的现金13,302,918.046,739,966.3128,062,295.3623,208,236.18
  支付其他与筹资活动有关的现金87,467,585.9648,869,439.52418,977,874.92316,013,738.35
  筹资活动现金流出小计1,072,270,504535,272,405.832,770,737,620.282,267,819,424.53
  筹资活动产生的现金流量净额389,229,496283,827,594.173,461,869.72-88,619,934.53
四、汇率变动对现金及现金等价物的影响3,156,614.348,909,457.0635,694,131.3613,615,220.99
五、现金及现金等价物净增加额450,706,693.16616,167,409.33-313,402,534.35-40,811,429.99
  加:期初现金及现金等价物余额936,128,317.42936,128,317.421,249,530,851.771,249,530,851.77
  期末现金及现金等价物余额1,386,835,010.581,552,295,726.75936,128,317.421,208,719,421.78
补充资料:
  净利润12,623,205.93--333,887,461.91-
  资产减值准备22,703,538.03-429,710,749.24-
  固定资产和投资性房地产折旧159,167,374.6-318,193,365.7-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧159,167,374.6-318,193,365.7-
  无形资产摊销10,004,511.65-20,040,380.72-
  长期待摊费用摊销782,127.92-1,564,255.88-
  处置固定资产、无形资产和其他长期资产的损失26,079.94--1,037,057.82-
  固定资产报废损失175,353.96--93,706.78-
  公允价值变动损失-6,903,972.57-16,490,493.01-
  财务费用12,732,441.04--6,230,914.04-
  投资损失3,170,767.32--8,783,878.95-
  递延所得税3,490,759.57--8,759,100.22-
  其中:递延所得税资产减少1,176,532.31--982,938.98-
    递延所得税负债增加2,314,227.26--7,776,161.24-
  存货的减少-111,184,165.2--264,233,562.75-
  经营性应收项目的减少25,443,647.95--340,299,947.31-
  经营性应付项目的增加-133,458,296.19-347,634,293.1-
  现金的期末余额1,386,835,010.58-936,128,317.42-
  减:现金的期初余额936,128,317.42-1,249,530,851.77-
  现金及现金等价物的净增加额450,706,693.16--313,402,534.35-
公告日期2025-08-302025-04-292025-04-292024-10-31
审计意见(境内)标准无保留意见
TOP↑